The utility of cerebrospinal fluid analysis in patients with multiple sclerosis (Q38092972)

28 August 2017

The utility of cerebrospinal fluid analysis in patients with multiple sclerosis (English)

1 reference

28 August 2017

0 references

0 references

5

Olaf Stüve

1 reference

28 August 2017

6

Hayrettin Tumani

1 reference

28 August 2017

Martin Stangel

1

1 reference

28 August 2017

Sten Fredrikson

series ordinal

2

1 reference

28 August 2017

Edgar Meinl

series ordinal

3

1 reference

28 August 2017

Axel Petzold

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

26 March 2013

1 reference

28 August 2017

Nature Reviews Neurology

1 reference

28 August 2017

9

1 reference

28 August 2017

267-276

1 reference

28 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2013.41

28 August 2017

0 references

cites work

FOUR CASES OF TUBERCULAR MENINGITIS IN WHICH PARACENTESIS OF THE THECA VERTEBRALIS WAS PERFORMED FOR THE RELIEF OF FLUID PRESSURE

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

AN ELECTROPHORETIC STUDY OF THE PROTEIN COMPONENTS IN CEREBROSPINAL FLUID AND THEIR RELATIONSHIP TO THE SERUM PROTEINS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Multiple sclerosis: measurement and validation of central nervous system IgG synthesis rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Cerebrospinal fluid biomarkers in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Multiple sclerosis with and without CSF bands: clinically indistinguishable but immunogenetically distinct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Elevated neurofilament levels in neurological diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Neurofilament ELISA validation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Accumulation of cortical hyperphosphorylated neurofilaments as a marker of neurodegeneration in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Tau protein: a possible prognostic factor in optic neuritis and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

A study of oligoclonal band negative multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

The prognostic significance of cerebrospinal fluid in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Intrathecal, polyspecific antiviral immune response in oligoclonal band negative multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

B cells and antibodies in multiple sclerosis pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

The relation between inflammation and neurodegeneration in multiple sclerosis brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Lipid microarrays identify key mediators of autoimmune brain inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Multiple Sclerosis Pathology: Evolution of Pathogenetic Concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Expression of CCR7 in multiple sclerosis: implications for CNS immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

B cells undergo unique compartmentalized redistribution in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Neurofascin as a novel target for autoantibody-mediated axonal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Oligoclonal "fingerprint" of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Immunological markers of optimal response to natalizumab in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

2D DIGE of the cerebrospinal fluid proteome in neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Fusion of metabolomics and proteomics data for biomarkers discovery: case study on the experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Proteomics technologies for biomarker discovery in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Autoantigen discovery with a synthetic human peptidome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Antigen microarrays identify CNS-produced autoantibodies in RRMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Potassium channel KIR4.1 as an immune target in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Axonal Loss and Neurofilament Phosphorylation Changes Accompany Lesion Development and Clinical Progression in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Electrophoretic morphology of gamma globulins in cerebrospinal fluid of multiple sclerosis and other diseases of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Isoelectric focusing of cerebrospinal fluid immunoglobulin G: an annotated update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Intrathecal synthesis in particular types of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

The role of MRI of the brain and spinal cord, and CSF examination for the diagnosis of primary progressive multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Clinical, MRI, CSF and electrophysiological findings in different stages of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Cerebrospinal fluid oligoclonal bands and progression of disability in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. The Optic Neuritis Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Influence of oligoclonal IgM specificity in multiple sclerosis disease course

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

MicroRNAs in the CSF: macro-advance in MS?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.41

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

31 March 2020

1 reference

12 December 2020

External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients

1 reference

12 December 2020

The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins

1 reference

12 December 2020

Diagnostic criteria for primary progressive multiple sclerosis: a position paper

1 reference

12 December 2020

Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy

1 reference

12 December 2020

The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis.

1 reference

12 December 2020

Electrophoresis of serum globulin. I.

1 reference

12 December 2020

Cerebrospinal fluid and serum gamma globulin levels in multiple sclerosis: changes induced by large doses of prednisone.

1 reference

12 December 2020

Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2013.41

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference